Review



complement preserved normal human serum (nhs)  (Complement Technology Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Complement Technology Inc complement preserved normal human serum (nhs)
    SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different <t>complement</t> pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% <t>NHS</t> containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.
    Complement Preserved Normal Human Serum (Nhs), supplied by Complement Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement preserved normal human serum (nhs)/product/Complement Technology Inc
    Average 90 stars, based on 1 article reviews
    complement preserved normal human serum (nhs) - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb"

    Article Title: SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb

    Journal: Blood Advances

    doi: 10.1182/bloodadvances.2022009028

    SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different complement pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% NHS containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.
    Figure Legend Snippet: SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different complement pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% NHS containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.

    Techniques Used: Control, Inhibition, Activation Assay, Hemolysis Assay, Incubation, Standard Deviation



    Similar Products

    complement preserved normal human serum (nhs)  (Complement Technology Inc)
    90
    Complement Technology Inc complement preserved normal human serum (nhs)
    SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different <t>complement</t> pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% <t>NHS</t> containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.
    Complement Preserved Normal Human Serum (Nhs), supplied by Complement Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complement preserved normal human serum (nhs)/product/Complement Technology Inc
    Average 90 stars, based on 1 article reviews
    complement preserved normal human serum (nhs) - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different complement pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% NHS containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.

    Journal: Blood Advances

    Article Title: SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb

    doi: 10.1182/bloodadvances.2022009028

    Figure Lengend Snippet: SAR443809 specifically inhibits AP without inhibiting CP or LP. SAR443809 and its corresponding IgG isotype control were tested in a series of assays to assess their ability to inhibit the different complement pathways. A dose-dilution series of SAR443809 (●) or IgG control antibody (○) were tested in the commercial Wieslab EIA assays for (A) AP, (C) CP, and (D) LP, in which the inhibition of MAC deposition upon pathway specific activation was assessed per manufacturer’s protocol. (B) Antibodies were also tested in AP hemolysis assay. Rabbit erythrocytes were incubated with 10% NHS containing Mg 2+ -EGTA in the presence of varying concentrations of either SAR443809 (●) or the isotype control (○). The extent of hemolysis was quantified using the absorbance of the released hemoglobin in the supernatant. The data reported here is a mean of 3 independent experiments ± standard deviation, for all 4 data sets.

    Article Snippet: Complement preserved normal human serum (NHS) was sourced from Complement Technology Inc (Tyler, TX), BioIVT (Westbury, NY), or Innovative Research (Novi, MI).

    Techniques: Control, Inhibition, Activation Assay, Hemolysis Assay, Incubation, Standard Deviation